Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ:AVIR
Total Valuation
Atea Pharmaceuticals has a market cap or net worth of $245.32M. The enterprise value is -$99.01M.
Market Cap$245.32M
Enterprise Value-$99.01M
Share Statistics
Atea Pharmaceuticals has 78,126,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,126,790
Owned by Insiders10.42%
Owned by Institutions22.68%
Financial Efficiency
Atea Pharmaceuticals’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -43.34%.
Return on Equity (ROE)-0.38
Return on Assets (ROA)-0.36
Return on Invested Capital (ROIC)-43.34%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee0.00
Profits Per Employee-3.01M
Employee Count56
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Atea Pharmaceuticals is ―. Atea Pharmaceuticals’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio0.64
Price to Fair Value0.64
Price to FCF-2.08
Price to Operating Cash Flow-2.27
PEG Ratio-0.07
Income Statement
In the last 12 months, Atea Pharmaceuticals had revenue of 0.00 and earned -168.38M in profits. Earnings per share was -2.00.
Revenue0.00
Gross Profit-83.37M
Operating Income-192.95M
Pretax Income-167.46M
Net Income-168.38M
EBITDA-131.80M
Earnings Per Share (EPS)-2.00
Cash Flow
In the last 12 months, operating cash flow was -134.21M and capital expenditures 0.00, giving a free cash flow of -134.21M billion.
Operating Cash Flow-134.21M
Free Cash Flow-134.21M
Free Cash Flow per Share-1.72
Dividends & Yields
Atea Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change-3.09%
50-Day Moving Average3.16
200-Day Moving Average3.17
Relative Strength Index (RSI)49.97
Average Volume (3m)424.40K
Important Dates
Atea Pharmaceuticals upcoming earnings date is Mar 3, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 3, 2026
Ex-Dividend Date―
Financial Position
Atea Pharmaceuticals as a current ratio of 24.85, with Debt / Equity ratio of 0.34%
Current Ratio24.85
Quick Ratio24.85
Debt to Market Cap<0.01
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Atea Pharmaceuticals has paid 925.00K in taxes.
Income Tax925.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Atea Pharmaceuticals EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.62.
EV to Sales0.00
EV to EBITDA-1.31
EV to Free Cash Flow-1.62
EV to Operating Cash Flow-1.62
Balance Sheet
Atea Pharmaceuticals has $329.31M in cash and marketable securities with $1.04M in debt, giving a net cash position of $328.26M billion.
Cash & Marketable Securities$329.31M
Total Debt$1.04M
Net Cash$328.26M
Net Cash Per Share$4.20
Tangible Book Value Per Share$5.21
Margins
Gross margin is -25.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-25.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Atea Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast14.33%